



LIST OF REFERENCES CITED BY APPLICANT

(Use ~~only~~ ~~only~~ if necessary)ATTY DOCKET NO
6750-214-999APPLICATION NO
10/687,035APPLICANT
Albone *et al.*FILING DATE
October 15, 2003GROUP
To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,921,790	5/1/90	O'Brien			
	A02	5,059,680	10/22/91	Devis <i>et al.</i>			
	A03	5,858,361	1/12/99	Wagner <i>et al.</i>			
	A04	5,976,818	11/2/99	O'Brien			
	A05	6,241,985	6/5/01	Madiyalakan <i>et al.</i>			
	A06	6,468,546	10/22/02	Mitcham <i>et al.</i>			
	A07	6,488,931	12/3/02	Mitcham <i>et al.</i>			
	A08	6,528,253	3/4/03	Mitcham <i>et al.</i>			
	A09	6,699,664	3/2/04	Mitcham <i>et al.</i>			
	A10	6,670,463	12/30/03	Mitcham <i>et al.</i>			
	A11	20020022591	2/21/02	Algate <i>et al.</i>			
	A12	20020119158	8/29/02	Algate <i>et al.</i>			
	A13	20030008299	1/9/03	Algate			
	A14	20030091580	5/15/03	Mitcham <i>et al.</i>			
	A15	20030124140	7/3/03	Bangur <i>et al.</i>			
	A16	20030165504	9/4/03	Retter <i>et al.</i>			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A17	WO0036107	6/22/00	PCT				
	A18	WO0206317	1/24/02	PCT				
	A19	WO0157207	8/9/01	PCT				
	A20	WO04005470	1/15/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	A21	Bast <i>et al.</i> (1981) "Reactivity of a Monoclonal Antibody with Human Ovarian Carcinn" <i>J. Clin Invest</i> 68(5): 1331-37.
	A22	Boshell <i>et al.</i> (1992) "The Product of the Human MUC1 Gene When Secreted by Mouse Cells Transfected With the Full-Length cDNA Lacks Cytoplasmic Tail" <i>Biochem and Biophys Res. Comm</i> 185(1):1-8.
	A23	Frailes <i>et al.</i> (1993) "Purification and Characterization of the CA 125 Tumor-Associated Antigen From Human Ascites" <i>Tumour Biol.</i> 1993;14(1):18-29.
	A24	Gadducci <i>et al.</i> (1992) "The Concomitant Determination of Different Tumor Markers in Patients with Epithelial Ovarian Cancer and Benign Ovarian Masses: Relevance for Differential Diagnosis", <i>Gynecol Oncol.</i> 44(2):147-54.
	A25	Hovig <i>et al.</i> (2001) "CA125: The End of the Beginning" <i>Tumor Bio.</i> 22:345-47.
	A26	Hu <i>et al.</i> (2003) "Discovery and Validation of New Molecular Targets of Ovarian Cancer" <i>Current Opinion in Molecular Therapeutics.</i> 5(6):625-630.
	A27	Kabawat <i>et al.</i> (1983) "Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types", <i>Am. J. Clin. Pathol.</i> 79:98-104.



	A28	Lichtenberg <i>et al.</i> (1992) "Cell-Associated Episialin Is a Complex Containing Two Proteins Derived From A Common Precursor" <i>The Journal of Biol. Chem.</i> 267(9):6171-77.
	A29	Madiyalakan <i>et al.</i> (1997) "Ovarex MAb-B43.13:IFN-Gamma Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cell" <i>Hybridoma</i> 16(1): 41-5.
	A30	Maeda <i>et al.</i> (2004) "Solution Structure of the SEA Domain From the Murine Homologue of Ovarian Cancer Antigen CA125 (MUC16)" <i>The Journal of Biol. Chem.</i> 279(13): 13174-13182.
	A31	Noujaim <i>et al.</i> (2001) "Induction of CA125-Specific B and T Cell Responses in Patients Injected With MAb-B43.13—Evidence for Antibody-Mediated Anti-processing and Presentation of CA125 <i>in Vivo</i> " <i>Cancer Biother. Radiopharm</i> 16(3): 187-203.
	A32	Nustad <i>et al.</i> (1996) "Specificity and Affinity of 26 Monoclonal Antibodies Against the CA 125 Antigen: First Report From the ISOBM TD-1 Workshop. International Society for Oncodevelopmental Biology and Medicine" <i>Tumour Biol.</i> 17(4): 196-219.
	A33	Nustad <i>et al.</i> (2002) "Epitopes on CA 125 From Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies. Third report from the ISOBM TD-1 workshop" <i>Tumour Biol.</i> 23(5): 303-314.
	A34	O'Brien <i>et al.</i> (2001) "The CA125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences" <i>Tumor Bio.</i> 22:348-366.
	A35	O'Brien <i>et al.</i> (2002) "The CA125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure" <i>Tumor Bio.</i> 23:154-169.
	A36	Saga <i>et al.</i> (1990) "Construction of an Immunoradiometric Assay for Ovarian Cancer Antigen CA125 Recognizing Different Antigenic Determinant" <i>ACTA Obstet Gynecol. Scand.</i> 69(2):175-81.
	A37	Saga <i>et al.</i> (1990) "An Antibody-Tumor Model for the Targeting of CA125-Producing Gynecologic Malignancies" <i>Jpn J. Cancer Res.</i> 81(11):1141-48.
	A38	Yin <i>et al.</i> (2001) "Molecular Cloning of the CA125 Ovarian Cancer Antigen" <i>The Journal of Biol. Chem.</i> 276(29):27371-375.


EXAMINER

DATE CONSIDERED


4/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO.		APPLICATION NO		
		6750-214-999		10/687,035		
		APPLICANT				
		Albone <i>et al.</i>				
		FILING DATE		GROUP		
		October 15, 2003		1632		
U.S. PATENT DOCUMENTS						
*EXAMINER INTL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B01 5,693,762	12/2/97	Queen <i>et al.</i>			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	B02 International Search Report of PCT/US03/32945	8/25/04	PCT				
	B03 WO04005470	1/15/04	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	B04:	Andersson, <i>et al.</i> , 1999 "Biokinetics of the Monoclonal Antibodies MOv 18, OV 185 and OV 197 Labelled with ¹²⁵ I According to the m-MeATe Method or the Iodogen Method in Nude Mice with Ovarian Cancer Xenografts", <i>ACTA Oncologica</i> , 38(3) 323-328.
	B05:	Bouvier, <i>et al.</i> , 1988 "Serum Levels of Tumor Markers and Presence of Human Antimouse Antibodies: Implications for Diagnosis and Treatment with Radiolabeled Monoclonal Antibodies", <i>Cancer Detection and Prevention</i> , 13: 251-262.
	B06:	Chatal, <i>et al.</i> , 1989 "Biodistribution of Indium-111-Labeled OC 125 Monoclonal Antibody Intraperitoneally Injected Into Patients Operated On for Ovarian Carcinomas", <i>Cancer Research</i> , 49: 3087-3094.
	B07:	Cuesta, <i>et al.</i> , 1999 "Tissue Quantifications of CA 125 in Epithelial Ovarian Cancer", <i>The International Journal of Biological Markers</i> , 14(2): 106-114.
	B08:	Gaetje, <i>et al.</i> , 1999 "Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometrial Cell Line EEC 145", <i>J. Soc. Gynecol. Invest.</i> , 6(5): 278-281.
	B09:	Haisma, <i>et al.</i> , 1987 "Antibody-Antigen Complex Formation Following Injection of OC125 Monoclonal Antibody In Patients With Ovarian Cancer", <i>Int. J. Cancer</i> , 40: 758-762.
	B10:	Imai, <i>et al.</i> , 1991 "Monoclonal Antibodies Against CA125-Bearing Antigenic Molecule Fragments; reactivity with Mucinous Ovarian Tumours and Lung Cancers", <i>Molecular and Cellular Probes</i> , 5: 55-63.
	B11:	Kalofonos, <i>et al.</i> , 1999 "Radioimmunosintigraphy In Patients With Ovarian Cancer", <i>ACTA Oncologica</i> , 38(5): 629-634.
	B12:	Kobayashi <i>et al.</i> , 1993 "A Human/Mouse Chimeric Monoclonal Antibody Against CA125 for Radioimmunoimaging of Ovarian Cancer", <i>Cancer Immunol. Immunother.</i> , 37: 143-149.
	B13:	Markman, Maurice 1997, "The Role of CA-125 in the Management of Ovarian Cancer", <i>The Oncologist</i> , 2: 6-9.
	B14:	Maier, <i>et al.</i> , 1992 "Human Antibody Response to the Intravenous and Intraperitoneal Administration of the F(ab) ₂ Fragment of the OC125 Murine Monoclonal Antibody", <i>Journal of Immunotherapy</i> , 11: 56-66.
	B15:	National Comprehensive Cancer Network Practice Guideline sin Oncology Version 1 2002 "Ovarian cancer Guideline"
	B16:	Nyhus, <i>et al.</i> , 2001 "IgG-Recognizing Shed Tumor-Associated Antigens Can Promote Tumor Invasion and Metastasis", <i>Cancer Immunol. Immunother.</i> , 50: 361-372.
	B17:	Osmer, <i>et al.</i> , 1997 "Does an Immunoscintigraphy With OC 125 Affect the Prognosis of Ovarian Cancer", <i>Eur J. Gynaec Oncol.</i> , 18(3): 177-182.
	B18:	Pimm, <i>et al.</i> , 1995 "Circulating Antigen: Bad or Good for Immunoscintigraphy?" <i>Nucl Med. Biol.</i> , 22(2): 137-145
	B19:	Reinartz, <i>et al.</i> , 2000 "Immunological Properties of a Single-Chain Fragment of the Anti-Idiotypic Antibody ACA125", <i>Cancer Immunol. Immunother.</i> , 49: 186-192.
	B20:	Reinsberg, <i>et al.</i> , 1994 "False Changes in CA125 Levels In Ovarian Cancer Patients After Infusion of OC 125 Fragments For Diagnostic and Therapeutic Purpose", <i>Arch Gynecol Obstet.</i> , 255: 9-18.

/LBG/	B21	Rustin, <i>et al.</i> , 2004 "Use of CA-125 In Clinical Trial Evaluation of New Therapeutic Drugs For Ovarian Cancer", <i>Clinical Cancer Research</i> , 10: 3919-3926.
/LBG/	B22	Seelenmeyer, <i>et al.</i> , 2002 "The Cancer Antigen CA125 Represents A Novel Counter Receptor For Galectin-1" <i>Journal of Cell Science</i> , 116(7): 1305-1318.
/LBG/	B23	Zeimet, <i>et al.</i> , 1997 "Modulation of CA-125 Release By Inflammatory Cytokines In Human Peritoneal Mesothelial and Ovarian Cancer Cells", <i>Anticancer Research</i> , 17: 3129-3132.

EXAMINER		DATE CONSIDERED	4/24/06
<p>*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			




LIST OF REFERENCES CITED BY APPLICANT
(Attach several sheets if necessary)

ATTY DOCKET NO. 6750-214-999	APPLICATION NO 10/687,035
APPLICANT Albone <i>et al.</i>	
FILING DATE October 15, 2003	GROUP To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
A	C01	2003-0104442 A1	6/5/03	Lloyd, <i>et al.</i>			
	C02	2004-0127401 A1	7/1/04	O'Brien			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	C03	EP 1256354	11/13/02	EPO				
	C04	WO02007783	1/31/02	PCT				
	C05	WO02083866	10/24/02	PCT				
	C06	WO02092836	11/21/02	PCT				
	C07	WO04045553	6/3/04	PCT				
	C08	WO03076473	9/18/03	PCT				
	C09	WO03076465	9/18/03	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A	C10	Beck, <i>et al.</i> (1994) "In Vitro Activity of Immunoconjugates Between Cisplatin and an Anti-CA125 Monoclonal Antibody on Ovarian Cancer Cell Lines", <i>Cell Biophysics</i> , 24(25): 163-173.
	C11	Beck, <i>et al.</i> (1998) "CA 125 Production and Release By Ovarian Cancer Cells In Vitro", <i>Int. J. Biol. Markers</i> , 13(4): 200-206 163-173.
	C12	Byrd, <i>et al.</i> (2004) "Mucins and Mucin Binding Proteins in Colorectal Cancer", <i>Cancer and Metastasis Reviews</i> , 23(1/2): 77-99.
	C13	Candido, <i>et al.</i> (2003) "CA 125 and Vascular Endothelial Growth Factor in the Differential Diagnosis of Epithelial Ovarian Tumors", <i>Gynecologic and Obstetric Investigation</i> , 54(3): 132-136.
	C14	Chang, <i>et al.</i> (2002) "Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer", <i>Journal of the National Cancer Institute</i> , 94(22): 1697-1703.
	C15	Davis, <i>et al.</i> (1986) "Characterization of the CA125 Antigen Associated With Human Epithelial Ovarian Carcinomas", <i>Cancer Research</i> , 46(12 Pt 1): 6143-6148.
	C16	Evans, <i>et al.</i> (2003) "Oregovomab", <i>American Journal of Cancer</i> (Auckland, New Zealand), 2(2): 125-133.
	C17	Fendrick, <i>et al.</i> (1997) "CA125 Phosphorylation Is Associated With Its Secretion From the WISH Human Amnion Cell Line", <i>Tumor Biology</i> , 18: 278-289.
	C18	Guppy, <i>et al.</i> (2002) "CA125 Response: Can It Replace the Traditional Response Criteria in Ovarian Cancer", <i>The Oncologist</i> , 7: 437-443.
	C19	Hu, <i>et al.</i> (2003) "Expression of Mucins and Cytokeratins In Ovarian Cancer Cell Lines", <i>Current Opinion in Molecular Therapeutics</i> , 5(6): 625-630.
	C20	Imbert-Marcille, <i>et al.</i> (1994) "Modulation of Associated Ovarian Carcinoma Antigens by 5 Cytokines Used As Single Agents Or In Combination", <i>Int. J. Cancer</i> , 57: 392-398.
	C21	Kabawat, <i>et al.</i> (1983) "Immunopathologic Characterization of a Monoclonal Antibody That Recognizes Common Surface Antigens of Human Ovarian Tumors of Serous, Endometrioid, and Clear Cell Types", <i>Am J. Clin. Pathol.</i> , 79(1): 98-104.
	C22	Lamerz, Rolf. (1998) "34.4 CA 125", <i>Gastrointestinal Cancer Antigens</i> , 34.4: 969-972.
	C23	Lloyd, <i>et al.</i> (1997) "Isolation and Characterization of Ovarian Cancer Antigen CA 125 Using a New Monoclonal Antibody (YK-8): Identification As A Mucin-Type Molecule", <i>Int. J. Cancer</i> , 71: 842-850.
	C24	Lloyd, <i>et al.</i> (2001) "Synthesis and Secretion of the Ovarian Cancer Antigen CA 125 by the Human Cancer Cell Line NIH:OVCA9-3", <i>Tumor Biology</i> , 22: 77-82.

C25	Manetta, et al. (1989) "Therapeutic Effects of A Radiolabeled Monoclonal Antibody on Human Ovarian Cancer Xenograft in Nude Mice", <i>Gynecologic Oncology</i> , 32: 368-370.
C26	Marth, et al. (1998) "Regulation of the CA 125 Expression in Cultured Human Carcinoma Cells", <i>The Int. J. of Biol. Markers</i> , 13(4): 207-209.
C27	Maughan, et al. (1990) "OC125 Immunoscintigraphy In Ovarian Carcinoma: A Comparison With Alternative Methods of Assessment", <i>Clinical Oncology</i> , 2: 199-205.
C28	McQuarrie, et al. (1997) "Pharmacokinetics and Radiation Dosimetry of ⁹⁰ Tc-Labelled Monoclonal Antibody B43.13 In Ovarian Cancer Patients", <i>Nuclear Medicine Communications</i> , 18: 878-886.
C29	McQuarrie, S.A. (1998) "The Effects of Circulating Antigen on the Pharmacokinetics and Radioimmunoscintigraphic Properties of ⁹⁰ Tc Labelled Monoclonal Antibodies in cancer Patients", <i>Journal Pharm. Pharmacol. Sci.</i> , 1(3): 115-125.
C30	Molthoff, et al. (1991) "Human Ovarian Cancer Xenografts In Nude Mice: Characterization and Analysis of Antigen Expression", <i>Int. J. Cancer</i> , 47: 72-79.
C31	Nap, et al. (1998) "Immunohistochemistry of CA 125 Unusual Expression in Normal Tissues, Distribution in the Human Fetus and Questions Around Its Application In Diagnostic Pathology", <i>The International Journal of Biological Markers</i> , 13(4): 210-215.
C32	Nakai, et al. (1993) "Changes in CA125 Release and Surface Expression Caused by Drugs in Uterine Cervix Adenocarcinoma Cells", <i>Annals of Nuclear Medicine</i> , 7(3): 133-139.
C33	Nustad, et al. (1998) "CA 125 - Epitopes and Molecular Size", <i>The Int. J. of Biol. Markers</i> , 13(4): 196-199.
C34	O'Brien, et al. (1998) "More Than 15 Years of the CA 125: What is Known About the Antigen, Its Structure and Its Function", <i>The Int. J. of Biol. Markers</i> , 13(4): 188-195.
C35	Prinszen, et al. (1998) "Biodistribution of ¹¹¹ In-Labelled Engineered Human Antibody CTM01 (HCTM01) In Ovarian Cancer Patients: Influence of Prior Administration of Unlabelled HCTM01", <i>Cancer Immunol. Immunother.</i> , 47: 39-46.
C36	Reinartz, et al. (2004) "Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotypic ACA125: Immunological Response and Survival (Phase Ib/II)", <i>Clinical Cancer Res.</i> , 10: 1580-1587.
C37	Reinartz, et al. (2003) "Interleukin-6 Fused to an Anti-Idiotypic Antibody in a Vaccine Increases the Specific Humoral Immune Response Against CA125 (MUC-16) Ovarian Cancer", <i>Cancer Res.</i> , 63: 3234-3240.
C38	Reinsberg, et al. (1999) "Falsely Low Results in CA 125 Determination Due to Anti-Idiotypic Antibodies Induced by In-Fusion of (¹³¹ I)F(ab)', Fragments of the OC125 Antibody", <i>Eur. J. Clin. Chem. Clin. Biochem.</i> , 31: 323-327.
C39	Rump, et al. (2004) "Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion", <i>The Journal of Biol. Chem.</i> , 279(10): 9190-9198.
C40	Sakahara, et al. (1996) "Effect of Circulating Antigen on Immunoscintigraphy of Ovarian Cancer Patients Using Anti-CA 125 Monoclonal Antibody", <i>Jpn. J. Cancer Research</i> , 87: 655-661.
C41	Schneider-Gadicke, et al. (1992) "Analysis of Cytotoxicity of ¹³¹ I-Labelled OC125 F(ab)', on Human Epithelial Ovarian Cancer Cell Lines", <i>Radiotherapy and Oncology</i> , 23: 150-159.
C42	Schorge, et al. (2004) "Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer", <i>Clinical Cancer Research</i> , 10(10): 3474-3478.
C43	Schultes, et al. (2003) "Monitoring of Immune Responses to CA125 with an IFN-gamma ELISPOT assay", <i>Journal of Immunological Methods</i> , 279(1-2): 1-15.
C44	Sjovall, et al. (2002) "The Significance of Serum CA 125 Elevation in Malignant and Nonmalignant Diseases", <i>Gynecologic Oncology</i> , 85: 175-178.
C45	Stimpff, et al. (1999) "Expression of Mucins and Cytokeratins In Ovarian Cancer Cell Lines", <i>Cancer Letters</i> , 145: 133-141.
C46	Sweet, et al. (1989) "Daunorubicin Conjugated to a Monoclonal Anti-CA125 Antibody Selectively Kills Human Ovarian Cancer Cells", <i>Gynecologic Oncology</i> , 34: 305-311.
C47	Verheijen, et al. (1999) "CA 125: Fundamental and Clinical Aspects", <i>Seminars In Cancer Biology</i> , 9: 117-124.
C48	Yin, et al. (2001) "Molecular Cloning of the CA125 Ovarian Cancer Antigen: Identification As A New Mucin (MUC16)", <i>American Society for Biochemistry and Molecular Biology, Manuscript</i> (MI 103554200) 1-28.
C49	Yin, et al. (2002) "Ovarian Cancer Antigen CA125 is Encoded by the MUC16 Mucin Gene", <i>Int. J. Cancer</i> , 98(5): 737-740.

EXAMINER

DATE CONSIDERED

4/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


LIST OF REFERENCES USED BY APPLICANT
 (Use several sheets if necessary)

ATTY DOCKET NO.

6750-214-999

APPLICATION NO

10/687,035

APPLICANT

Albone *et al.*

FILING DATE

October 15, 2003

GROUP

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D01	5,366,866	11/22/94	Xu, <i>et al.</i>			
	D02	5,486,456	1/23/96	Xu, <i>et al.</i>			
	D03	5,650,291	7/22/97	Lee			
	D04	5,871,941	2/16/99	Auersperg			
	D05	6,376,654	4/23/02	Gelber			
	D06	2002-0009451	1/24/02	O'Brien			
	D07	2002-0037287	3/28/02	Gelber			
	D08	2002-0081609	6/27/02	Dillon, <i>et al.</i>			
	D09	2003-0082655	9/9/02	O'Brien			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	D10	EP 0 332 651 B2	12/27/96	EPO			
	D11	WO89/01629	2/23/89	PCT			
	D12	WO94/27637	8/12/94	PCT			
	D13	WO96/31539	10/10/96	PCT			
	D14	WO00/36107	6/22/00	PCT			
	D15	WO01/40269	6/7/01	PCT			
	D16	WO01/60860	8/23/01	PCT			
	D17	WO01/70804	9/27/01	PCT			
	D18	WO01/70979	9/27/01	PCT			
	D19	WO01/75177	10/11/01	PCT			
	D20	WO01/85203	11/15/01	PCT			
	D21	WO02/00677	1/3/02	PCT			
	D22	WO02/071928	9/19/02	PCT			
	D23	WO02/074961	9/26/02	PCT			
	D24	WO02/076384	10/3/02	PCT			
D25	WO02/092836	11/21/02	PCT				

EXAMINER

DATE CONSIDERED

4/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.